Skip to main content

AAN: Prophylactic Zonisamide Effective in Pediatric Migraine

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 3, 2025.

via HealthDay

MONDAY, March 3, 2025 -- For pediatric patients with migraine, prophylactic zonisamide use can significantly reduce the median number of headache days per month (HDPM), according to a study scheduled for presentation at the annual meeting of the American Academy of Neurology, to be held from April 5 to 9 in San Diego.

Isabelle Kang, from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined zonisamide prophylaxis and reduction in HDPM in pediatric patients with migraine in a retrospective cohort study conducted at a single institution. A total of 256 patients (70 percent female) were included in the study, with a median age of 15 years.

The researchers found that 28 percent of the patients had intractable migraine (had failed two or more prophylactic medications). At first follow-up after zonisamide initiation, there was a median decrease from 16 to six HDPM for the entire cohort. The group that followed up within two to six months demonstrated the largest reduction, with a median decrease of six HDPM. At first follow-up, there was a significant median decrease of six HDPM seen in both intractable and nonintractable groups.

"Migraine disease is debilitating and can lead to kids having to miss school and other activities," coauthor Anisa Kelley, M.D., also from the Northwestern University Feinberg School of Medicine, said in a statement. "Currently, there is only one FDA-approved migraine preventative medication for this age group. Our results are encouraging, showing zonisamide may be another option for reducing migraine attacks."

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM

WEDNESDAY, Aug. 6, 2025 -- Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus...

About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease

WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...

Follow-Up on Blood-Based Colorectal Cancer Screening Results Is Low

TUESDAY, Aug. 5, 2025 -- Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.